Delving into the Latest Updates on Teva NI Ltd. with Synapse

概览

关联

1

项与 Teva NI Ltd. 相关的药物

Testosterone

睾酮

靶点

AR

作用机制

AR激动剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1995-09-29

100 项与 Teva NI Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Teva NI Ltd. 相关的专利（医药）

登录后查看更多信息

3

项与 Teva NI Ltd. 相关的文献（医药）

2020-07-15·Journal of Chemistry

Development of Polymer and Surfactant Based Naringenin Nanosuspension for Improvement of Stability, Antioxidant, and Antitumour Activity

作者: Haque, Anzarul ; Akhter, Sohail ; Aldawsari, Hibah M. ; Choudhury, Hira ; Sivakumar, Ponnurengam Malliappan ; Alhakamy, Nabil A. ; Alharbi, Waleed S. ; Awan, Zuhier A. Y. ; Md, Shadab

Nanosuspensions are widely reported to enhance the solubility of poorly soluble drugs. In addition to enhancement in solubility, improvement of stability and therapeutic efficacy would be an added advantage. In the present study, premilling and subsequent high-pressure homogenization were carried out to produce naringenin nanosuspension. Hydroxypropyl methylcellulose and sodium dodecyl sulfate were evaluated for their performance as stabilizers under various homogenization cycles. The prepared nanosuspensions were studied for average particle size and size distribution, zeta potential, solubility, drug release, antioxidant activity, and in vitro antitumor activity. It was observed that both hydroxypropyl methylcellulose-stabilized nanosuspension and sodium dodecyl sulfate-stabilized nanosuspension produced an enhancement in physical stability, antioxidant potential, and in vitro cytotoxicity compared with naringenin. Furthermore, hydroxypropyl methylcellulose-stabilized nanosuspension was found to be better than sodium dodecyl sulfate-stabilized nanosuspension in terms of particle size and size distribution, storage stability, and drug release. This study showed that nanosuspension formulations could be a potential strategy for improving dissolution and antitumor activity of naringenin.

2013-11-01·Alimentary Pharmacology & Therapeutics1区 · 医学

Commentary: 5-ASA switches in IBD, adherence and flares - authors' reply

1区 · 医学

Article

作者: Wiseman, G. ; Robinson, A. ; Jones, M. ; Hankins, M.

A review.A polemic in response to Dr.Selinger et al is given.Dr.Selinger et al stated that medication switches in stable patients appear to exert an adverse effect.This study shows that switches in a subgroup of adherent patients lead to an increase in flares, but the study was not designed to measure how adherence changed after a flare.Furthermore, the author not suggesting that flares are solely due to pharmacol. effects, rather those pharmacol. effects are one of a number of potential contributing factors.

2013-09-01·Alimentary Pharmacology & Therapeutics1区 · 医学

Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse

1区 · 医学

Article

作者: Wiseman, G. ; Robinson, A. ; Jones, M. ; Hankins, M.

BACKGROUNDMaintenance therapy with 5-aminosalicylic acid (5-ASA) is a key strategy for preventing relapse in many patients with inflammatory bowel disease (IBD). Factors which disrupt 5-ASA delivery, such as non-adherence and 5-ASA switches, may destabilise symptom control.AIMTo investigate the impact of non-adherence and medication switches on stable symptom control in UK patients with IBD.METHODSA retrospective cohort study was conducted using a UK dispensing database. Adherence was analysed in randomised matched samples for each of the six leading oral mesalazine formulations, measured by medication possession ratio (MPR); MPR ≥80% was classified as adherent. Relationships among adherence, switch and relapse were analysed over 18 months in patients receiving continuous mesalazine therapy throughout a 6-month baseline period (primary subgroup analysis). Relapses of active ulcerative colitis were identified using a doubling of MPR as a proxy.RESULTSOnly 39% of patients in the matched samples (n = 1200) were classed as adherent. No significant differences in adherence were observed among mesalazine formulations. In the primary subgroup analysis (n = 568), non-adherent patients had a significantly greater risk of relapse than adherent patients (RR = 1.44, 95% CI = 1.08-1.94; P = 0.014). Among adherent patients (n = 276), those who switched had a 3.5-fold greater risk of relapse than those who did not switch (95% CI = 1.16-10.62; P = 0.008).CONCLUSIONSBoth non-adherence and mesalazine switches in adherent patients were associated with significant increases in the risk of relapse, suggesting that disruption of mesalazine maintenance therapy may destabilise symptom control. These findings provide evidence to advocate caution when considering mesalazine switches for stable patients.

100 项与 Teva NI Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Teva NI Ltd. 相关的转化医学

登录后查看更多信息